创响生物与Ikena Oncology达成合并协议,完成7500万美元融资

界面
25 Dec 2024

当地时间12月23日,创响生物(Inmagene)在官网宣布已与Ikena Oncology(Nasdaq: IKNA)达成最终合并协议。此次交易预计将带来约1.75亿美元(包括7500万美元的超额认购私募融资),用于合并后的公司进一步开发针对OX40的单克隆抗体IMG-007,用于治疗特应性皮炎。合并后的公司计划以“ImageneBio, Inc.”的名称运营,并在纳斯达克以“IMA”的股票代码...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10